-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Brand | Therapeutic category |
|---|---|
|
Coloxyl |
Emollient |
|
Dymadon |
Analgesic |
|
Gastro-Stop |
Anti-diarrhoeal |
|
Maltofer |
Iron supplement |
|
Xylocaine |
Regional anaesthetic |
0
Products
Launched
Launched
(2023: 16)
0
Product
Recalls
Recalls
(2023: 1)
0
%
Average Staff
Turnover
Turnover
(2023: 18%)
0
Work-related
Facilities
Facilities
(2023: Nil)
0
Sales
Representatives
Representatives
(2023: 77)
400
Permanent
Employees
Employees
(June 2024)
400
Permanent
Employees
Employees
(June 2023)
0
Products
Launched
Launched
(2022: 8)
Product
Recalls
Recalls
(2022: Nil)
0
%
Average Staff
Turnover
Turnover
(2022: 12%)
Work-related
Facilities
Facilities
(2022: Nil)
30
Sales
Representatives
Representatives
(2022: 83)
200
Permanent
Employees
Employees
(June 2022: 563)
| Revenue |
2024 R’million |
2023 (CER) R’million |
Change % |
|---|---|---|---|
|
Commercial Pharmaceuticals |
5 904 |
5 987 |
(1) |
|
Prescription |
2 618 |
2 788 |
(6) |
|
Over the counter |
2 430 |
2 340 |
4 |
|
Injectables |
856 |
859 |
- |
|
Manufacturing |
|
|
|
|
Finished dose form |
781 |
746 |
5 |
|
Total |
6 685 |
6 733 |
(1) |
Note: Commercial Pharmaceuticals’ revenue is by customer geography and Manufacturing revenue is by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 85
- Australasia15
Revenue by segment (%)
- Prescription39
- Over the counter36
- Injectables 13
- Finished dose form 12
- The Australian Hospital and Retail pharmaceutical market (excluding Vitamins and Minerals category) grew 3% to AUD24,3 billion. Within the Retail category, the OTC category grew 1,7% in value.
Source: IQVIA June 2024.
